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a b s t r a c t
Sleep-disordered breathing (SDB) is a common comorbidity in a number of cardiovascular
diseases, and mounting clinical evidence demonstrates that it has important implications in
the long-term outcomes of patients with cardiovascular disease (CVD). While recognition
among clinicians of the role of SDB in CVD is increasing, it too often remains neglected in the
routine care of patients with CVD, and therefore remains widely undiagnosed and untreat-
ed. In this article, we provide an overview of SDB and its relationship to CVD, with the goal of
helping cardiovascular clinicians better recognize and treat this important comorbidity in
their patients. We will describe the two major types of SDB and discuss the pathophysiologic,
diagnostic, and therapeutic considerations of SDB in patients with CVD.
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Worldwide, the incidence of cardiovascular disease (CVD)
continues to increase, and despite ongoing therapeutic
advances, it continues to be associated with high rates of
morbidity, hospitalization, and mortality.1,2 In India alone,
CVD is responsible for an estimated 20% of the nation's total
annual deaths—a number that is likely to climb as the nation's
rapid economic development and changing lifestyles fuel
known risk factors for CVD, such as obesity, diabetes,
dyslipidemia, and hypertension.3,4
The onward march of CVD throughout the world clearly
illustrates the need for new and innovative management
strategies to further improve patient outcomes. One area
under active investigation is the treatment of sleep-disordered
breathing (SDB), which is now recognized as a common
comorbidity in a number of CVDs. Mounting clinical evidence* Corresponding author.
E-mail address: s.anker@cachexia.de (S.D. Anker).
http://dx.doi.org/10.1016/j.ihj.2015.11.018
0019-4832/# 2015 Cardiological Society of India. Published by Elseviersuggests that the presence of SDB may have important
implications on the long-term outcomes of patients with CVD.
In this article, we provide an overview of SDB and its
relationship to CVD, with the goal of helping cardiovascular
clinicians better recognize and treat this important comorbid-
ity in their patients. Below, we describe the two major types of
SDB and discuss the pathophysiologic, diagnostic, and
therapeutic considerations of SDB in patients with CVD.
2. Deﬁnitions
SDB is characterized by cycles of signiﬁcant pauses in
breathing followed by hypoxia and partial neurological
arousals that disrupt sleep. An expanding body of research
shows that repeated episodes of apnea, hypoxia, and arousal
from sleep are associated with a number of pathophysiological
effects that have important clinical consequences, including, a division of Reed Elsevier India, Pvt. Ltd. All rights reserved.
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and CVD.5
Terms commonly used to describe the abnormal breathing
patterns associated with SDB include: apnea, the complete
absence of breathing (≥10 s); hypopnea, an abnormally slow or
especially shallow breathing; and hyperpnea, an abnormally
rapid or deep breathing. The apnea-hypopnea index (AHI) is a
commonly used clinical index that describes the severity of
SDB. The AHI is deﬁned as the average number of apnea and/or
hypopnea episodes that occur during sleep expressed in
events per hour. SDB severity is commonly deﬁned as mild
with an AHI ≥5 and <15, moderate with an AHI ≥15 and ≤30, or
severe with an AHI >30.
3. Types, prevalence, and pathophysiology
SDB is classiﬁed into two types: obstructive sleep apnea (OSA)
and central sleep apnea (CSA). Although it is not uncommon to
see a mixture of both types in a patient with CVD (especially in
patients with heart failure), one type usually predominates
throughout the sleep period. OSA is caused by partial or
complete upper airway collapse and obstruction during sleep.
Each episode of airway obstruction is associated with
decreased or absent air entry into the lungs and subsequent
hypoxia despite ongoing respiratory effort. Airway obstruction
is eventually terminated by an arousal from sleep. OSA is a
relatively common sleep disorder worldwide, occurring in an
estimated 3–8% of men and 1–5% of women.6 Although
research into the prevalence of OSA in the Indian population
is limited, one study found that 7.5% of middle-aged urban
Indian men may have OSA.7 In otherwise healthy individuals,
the presence of OSA is recognized as an important risk factor
for the development of a number of CVDs, including
hypertension,8,9 coronary artery disease,10,11 and stroke.12,13
OSA is also a common comorbidity in patients with estab-
lished CVD, occurring in an estimated 30% of hypertensive
patients,14,15 35% of heart failure patients,16,17 and 30% of
coronary artery disease patients.10,18 In these individuals, OSA
has been found to be an independent risk factor for the
progression of CVD and adverse outcomes.5 In patients with
heart failure, co-morbidities play an important role in the
progression of cardiac dysfunction and overall patient
status,19–21 and OSA, together with CSA, appear to be one of
most prevalent co-morbidities in these patients.
CSA is characterized by the temporary withdrawal of
central neurological respiratory drive, resulting in the cessa-
tion of respiratory effort and airﬂow. Whereas OSA is common
in the general population and is a comorbidity in a number of
CVDs, CSA is more uniquely seen in patients with heart failure
or following stroke.5 In these patients, CSA is typically
accompanied by Cheyne-Stokes respiration. CSA with
Cheyne-Stokes respiration is recognized by the simultaneous
absence of air ﬂow and respiratory effort (central apnea or
hypopnea) followed by characteristic hyperventilation in a
crescendo-decrescendo pattern. CSA in patients with heart
failure has been particularly well-studied. Because of its
unique relationship to heart failure and recent developments
in this area, our discussion of CSA will be limited to its
presence in heart failure. CSA is highly prevalent in heartfailure, occurring in about 35% of cases.16,22 Studies suggest
that CSA is an independent risk factor for cardiac transplan-
tation and death in patients with heart failure.23,24
Underlying the development of CSA in heart failure is
respiratory control system instability due to oscillation of the
arterial blood carbon dioxide level (PaCO2) above and below the
central threshold of ventilation termed the apneic threshold.25
A number of factors contribute to respiratory control system
instability and predispose heart failure patients to ﬂuctuations
in PaCO2, including lung congestion-related J-receptor activa-
tion, hypersensitive central and peripheral carbon dioxide
chemoreceptor gain, hypoxia-related arousals, as well as
reduced cardiac output leading to prolonged circulation time.26
When the PaCO2 is periodically driven below the apneic
threshold by an episode of hyperpnea—such as that which
occurs with hyperventilation during arousal or changes in sleep
stage—central neural outﬂow to the respiratory muscles is
temporarily suppressed and central apnea ensues.25,26
Despite differing mechanisms underlying the development
of OSA and CSA, both disorders are characterized by repeated,
prolonged apneas that result in hypoxia and partial neurolog-
ical arousals that signiﬁcantly disrupt sleep. These repeated
episodes of apnea, hypoxia, and arousal trigger a number of
neurohormonal, hemodynamic, metabolic, thrombotic, and
inﬂammatory mechanisms that place patients with SDB at
signiﬁcantly greater risk for hypertension, myocardial ische-
mia, arrhythmias, and ventricular dysfunction (Fig. 1). To-
gether, these effects ultimately contribute to the increased
morbidity and mortality seen in patients with SDB.5,26,27
4. Risk factors and clinical presentation
Risk factors associated with the development of OSA include
obesity, male gender, advancing age, genetic predisposition to
OSA, smoking and alcohol consumption, and craniofacial/
pharyngeal anatomical anomalies.6 Obesity is a major risk
factor in part because obese individuals often have periphar-
yngeal fatty deposits that contribute to pharyngeal obstruction.
Pharyngeal anatomical anomalies are another major risk factor
because they reduce the size of the posterior airway, which
increases the chance of obstruction during sleep. The classic
signs and symptoms of OSA are loud snoring, disrupted sleep,
and daytime drowsiness. Other symptoms may include
nocturnal gasping, restless legs, morning headaches, mood
changes, and trouble concentrating.5,27On clinical examination,
patients with OSA are typically middle-aged, overweight, and/or
may have craniofacial or pharyngeal features (e.g., presence of
redundant pharyngeal tissue, elongated soft palate, enlarged
uvula, and/or small or receding jaw) that contribute to upper
airway obstruction.5,27 Additionally, they often have elevated
daytime systolic blood pressure.5 In this regard, it should be
noted that many patients with drug-resistant hypertension
have undiagnosed OSA; thus, clinicians should maintain a high
level of suspicion of OSA when encountering these patients.5
Risk factors for CSA are closely associated with those of
heart failure, and include male gender, higher New York Heart
Association class, lower left ventricular ejection fraction,
waking hypocapnia, presence of atrial ﬁbrillation, higher brain
natriuretic peptide (BNP) levels, and frequent nocturnal
Fig. 1 – The pathophysiologic consequences of sleep-disordered breathing. Despite differing mechanisms underlying the
development of obstructive sleep apnea and central sleep apnea, both disorders are characterized by repeated, prolonged
apneas that result in hypoxia and partial neurological arousals that significantly disrupt sleep. These repeated episodes of
apnea, hypoxia, and arousal trigger various neurohormonal, hemodynamic, metabolic, thrombotic, and inflammatory
mechanisms that place patients with sleep-disordered breathing at significantly greater risk for hypertension, myocardial
ischemia, arrhythmias, and ventricular dysfunction. Abbreviations: CSA, central sleep apnea; LDL, low density lipoprotein;
NE, norepinephrine; OSA: obstructive sleep apnea; RAAS, renin-angiotensin-aldosterone system; SDB: sleep-disordered
breathing; SNS, sympathetic nervous system.
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not as typical as in OSA. Signs and symptoms associated with
CSA include insomnia, excessive daytime sleepiness, and/or
fatigue.5 Sometimes a sleep partner may report witnessed
apneas or the unusual breathing pattern of Cheyne-Stokes
respiration. Patients may also report frequent awakenings,
poor quality sleep, and/or shortness of breath.5 Paroxysmal
nocturnal dyspnea may also be seen with CSA.5 However,
since many of these ﬁndings are common to heart failure, the
presence of CSA is often overlooked by patients and clinicians,
and thus may lead to its under-diagnosis.
5. Diagnosis
The gold standard for diagnosing SDB is polysomnography, or
the overnight sleep study, which is performed in a sleeplaboratory. During polysomnography, various sensors are
placed on the patient to monitor and record brain electrical
activity, eye movements, heart rate and rhythm, breathing
rate and rhythm, blood oxygen level, and chest, abdominal,
and limb movements. The overnight sleep study is continu-
ously supervised by a trained technician and scored by a sleep
specialist.
The sleep study reports a number of key sleep variables,
including the AHI. Based on current guidelines, the diagnosis of
OSA is conﬁrmed if the number of obstructive events (obstruc-
tive apneas, hypopneas + respiratory event related arousals)
during the sleep study is greater than 15 events/hour, or greater
than 5 events/hour in a patient who reports any of the following:
unintentional sleep episodes during wakefulness; daytime
sleepiness; non-refreshing sleep; fatigue; insomnia; waking
up breath holding, gasping, or choking; or the bed partner
describing loud snoring, breathing interruptions, or both during
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if respiratory monitoring demonstrates at least three consecu-
tive cycles of crescendo-decrescendo change in breathing
amplitude and one or both of the following: (1) ﬁve or more
central sleep apneas or hypopneas per sleep hour and/or (2)
cyclical crescendo-decrescendo breathing ≥10 consecutive
minutes.31
An overnight sleep study performed in a sleep laboratory is
a labor-intensive, time-consuming, and expensive test. Avail-
ability and timely access for testing are other potential
concerns. There has, therefore, been increasing interest in
the use of portable, home-based, overnight sleep monitors to
diagnose SDB. Although many of these devices lack the
sensitivity and/or speciﬁcity for diagnosing SDB, recent
research suggests that Level III devices, which at a minimum
record oxygen, nasal ﬂow, and thoracic and abdominal
movement, offer good diagnostic performance compared with
polysomnography in patients with a high pretest probability of
moderate to severe OSA and no unstable comorbidities.32
However, for patients suspected of having CSA, polysomno-
graphy remains the diagnostic standard.
Finally, it is worth noting that several short patient
questionnaires, such as the Epworth Sleepiness Scale and
the Berlin Questionnaire, have been developed to help screen
for OSA (but not CSA) in the general population. These
questionnaires ask subjects to rate their likelihood of falling
asleep in several common situations. In the general popula-
tion, the scores from these questionnaires have been shown to
correlate reasonably well with the presence and severity of
OSA.33,34 In the CVD population, however, their utility remains
unclear. In heart failure patients, for example, they have not
been found effective in screening for OSA.35 Their lack of
sensitivity and speciﬁcity in the heart failure population is
likely due to the questionnaires' emphasis on subjective
daytime sleepiness caused by chronically disrupted sleep—a
ﬁnding that is signiﬁcantly less common in patients with HF,
and cardiac dysfunction in general.35 Thus, the use of
sleepiness questionnaires to screen for SDB is probably best
avoided in this population.
6. Treatment
6.1. OSA
A number of therapies are available to effectively treat OSA.
Which therapy is chosen depends in large part on the results of
the sleep study. For patients with mild OSA, weight loss for
those who are obese and avoiding the supine sleeping position
may successfully resolve OSA events. For moderate to severe
cases of OSA, the gold standard treatment is continuous
positive airway pressure (CPAP).30 CPAP therapy is delivered
using a tight ﬁtting nasal or facial mask through which
constant positive air pressure is applied to maintain airway
patency. OSA patients treated with CPAP often experience
rapid and signiﬁcant improvement in their AHI, nocturnal
symptoms, daytime sleepiness, and fatigue.36,37 Clinically,
studies have shown that CPAP treatment favorably effects
diurnal and nocturnal systolic and diastolic blood pressure38;
improves serum total cholesterol and triglyceride levels39,40;reduces serum levels of inﬂammatory markers, including
C-reactive protein, tumor necrosis factor a, and interleukin 6,
which contribute the atherosclerosis process41; and decreases
the incidence of fatal and nonfatal cardiovascular events.42 In
patients with drug-resistant hypertension and OSA, CPAP
therapy has been shown to result in favorable reductions in
both systolic and diastolic blood pressure.43 Other studies have
shown that in patients with OSA and pre-existing coronary
artery disease, treatment with CPAP protects against new
cardiovascular events.44 In studies of heart failure patients
with OSA, CPAP therapy has been shown to reduce nocturnal
blood pressure and heart rate and improve left ventricular
function.45–47 One small, nonrandomized trial reported that
CPAP may reduce the risk of death and hospitalization among
patients with heart failure and OSA.48
Successful treatment of OSA with CPAP requires that it be
used consistently every night for a prescribed number of
hours. Unfortunately, patient noncompliance with CPAP
therapy is a common problem.49 Reasons for poor compliance
include mask discomfort, nasal discharge or dryness, difﬁculty
breathing against positive airway pressure, mask-related
claustrophobia, and nighttime panic attacks. Many of these
complaints can be addressed through modiﬁcations in therapy
parameters. Nonetheless, many patients will still not tolerate
long-term CPAP therapy. Beyond CPAP, a number of other
therapies have been devised to treat OSA. They include
custom-made oral appliances and tongue retaining devices
that prevent pharyngeal obstruction during sleep; nasal
devices worn over each nostril that create increased expiratory
nasal resistance to maintain upper airway patency; various
surgical procedures, such as uvulopalatopharyngoplasty, that
enlarge the pharyngeal airway; oral negative pressure therapy,
which draws the tongue and soft palate anteriorly using a
mouthpiece connected to a suction mechanism; and hypo-
glossal nerve stimulation therapy, which stimulates key
airway muscles to maintain upper airway patency.50 It is
important to note, however, that none of these therapies have
been found to be as effective as CPAP in reducing or
eliminating OSA. Thus, these alternative therapies should
be reserved for those patients who do not respond to or simply
cannot tolerate CPAP therapy.
6.2. CSA
In contrast with OSA, the optimal treatment strategy for CSA
is much less clear. What is known, however, it that once heart
failure is clinically improved, CSA often improves as well.51–53
Therefore, optimizing treatment based on current heart
failure medical management guidelines is of foremost
importance.54–57 Unfortunately, CSA often persists in many
patients despite optimal heart failure therapy. This is
especially true in patients with more advanced heart failure.
Thus, for these patients, other targeted treatments for CSA
must be considered.
Positive airway pressure (PAP) therapies, such as CPAP and
adaptive pressure support servoventilation (ASV), have been
the most widely prescribed and extensively investigated
treatment for CSA in patients with heart failure.58 However,
two large, randomized, controlled trials have failed to show
improvement in morbidity and mortality with the use of PAP
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study, the Canadian Continuous Positive Airway Pressure for
Patients with Central Sleep Apnea and Heart Failure
(CANPAP) Trial, randomly assigned optimally medically
treated heart failure patients with CSA to receive either
CPAP or no CPAP to determine whether the use of CPAP
improved transplant-free survival.59 Overall, no mortality
beneﬁt was found; in fact, early divergence of survival curves
favoring the non-CPAP group resulted in the early termina-
tion of the study. However, after a mean follow-up of two
years, mortality was found to be similar in both groups. A
post-hoc analysis of the CANPAP data suggested that
insufﬁcient reduction in the AHI, poor patient compliance
with CPAP therapy, as well as the adverse effects PAP may
have had on cardiopulmonary function (primarily due to
PAP-induced increased intrathoracic pressure, which ad-
versely affects both right and left ventricular preload and
afterload) likely contributed to the disappointing results of
the CANPAP study.60,61 The second study, Treatment of
Predominant Central Sleep Apnea by Adaptive Servo Venti-
lation in Patients with Heart Failure (SERVE-HF) Trial,
evaluated the effect of treatment with ASV on morbidity
and mortality in patients with chronic heart failure and
CSA.62 ASV was designed to provide a more patient-tailored
PAP therapy in order to reduce the adverse cardiovascular
and pulmonary effects seen with CPAP treatment and to
improve patient compliance with therapy. Recently reported
results of the SERVE-HF Trial showed no signiﬁcant differ-
ence between patients treated with ASV and those in the
control group for the primary endpoints of time to all-cause
mortality, life-saving cardiovascular intervention, or un-
planned hospitalization for worsening heart failure. More
importantly, there was a statistically signiﬁcant 2.6% abso-
lute increased annual risk of cardiovascular mortality for
those randomized to ASV therapy compared to the control
group.63,64 However, two other large, randomized trials
evaluating ASV in the treatment of SDB in HF—the Effect
of Adaptive Servo Ventilation on Survival and Hospital
Admissions In Heart Failure (ADVENT-HF) and Cardiovascu-
lar Improvements With Minute Ventilation-targeted ASV
Therapy in Heart Failure (CAT-HF)—are ongoing, although
CAT-HF will not be enrolling patients with an ejection
fraction less than 45%.65,66
Although PAP-based therapies have garnered much of the
attention of researchers in recent years, a number of other
therapies have also been proposed and studied. These
therapies include nocturnal oxygen supplementation, atrial
pacing, pharmacologic agents (e.g., theophylline and acetazol-
amide), and nocturnal carbon dioxide administration. Al-
though small, preliminary trials have shown each to be of
some beneﬁt in reducing CSA and/or its symptoms, none have
undergone large scale, prospective, randomized trials to
establish their long-term safety and efﬁcacy. Further research
is needed to generate more conﬁdence in their effectiveness
and to justify their use for the chronic management of CSA in
patients with heart failure.58
Recently, a new physiologic approach to the treatment of
CSA has been introduced, and is currently completing follow-
up in a randomized, controlled clinical trial. It is an implant-
able, lead-based device similar in appearance to a pacemakerthat delivers unilateral transvenous phrenic nerve stimulation
to cause diaphragmatic contraction similar to a normal breath.
This diaphragmatic stimulation and subsequent contraction
create negative intrathoracic pressure so that airﬂow is
augmented and central apneas occurring during sleep are
prevented. It is worth noting that this mechanism of action is
very different than that of PAP therapy, which, by forcing air
into the lungs under pressure, acts to increase intrathoracic
pressure. Thus, with application of transvenous phrenic nerve
stimulation therapy, cyclical periodic breathing and blood gas
alterations are prevented. Additionally, as an implantable,
lead-based device therapy, this system should avoid any
patient compliance issues with treatment. Early studies using
this therapy have shown signiﬁcant improvement in major
indices of CSA severity, although its effects on heart failure-
related hospitalization, morbidity, and mortality remain
unknown.67,68 Active research with this system is currently
ongoing. This includes a pivotal clinical trial to evaluate the
chronic safety and efﬁcacy of unilateral phrenic nerve
stimulation using a fully implanted system. Results of this
trial are expected to be reported in 2016.
7. Conclusion
SDB is a common comorbidity in a number of CVDs, and
mounting clinical evidence demonstrates that it has impor-
tant implications for the long-term outcomes of patients with
CVD. While recognition among clinicians of the role of SDB in
CVD is increasing, it remains too often neglected in the routine
evaluation and management of patients with CVD, and thus it
remains widely undiagnosed and untreated. This is unfortu-
nate, since by simply asking a few additional questions about a
patient's sleep habits and related symptoms at each ofﬁce visit
or hospital admission, patients in need of further diagnostic
testing could be readily identiﬁed.
Polysomnography, or the overnight sleep study, remains
the gold standard for diagnosing SDB. However, it is an
expensive, labor-intensive, and time-consuming test, and
availability and timely access for testing are common
concerns. Portable, home-based, Level III devices offer good
diagnostic performance compared with polysomnography in
patients with a high pretest probability of moderate to severe
OSA and no unstable comorbidities, and thus may be
considered when polysomnography is unavailable. However,
for patients suspected of having CSA, polysomnography
remains the diagnostic standard.
A number of different treatment options are available to
effectively treat OSA. Of these, CPAP is the primary treatment,
as it has been shown to be highly effective in controlling
symptoms, improving quality of life, and reducing the clinical
consequences of OSA. In contrast, the optimal treatment of
CSA in patients with heart failure remains unclear. When CSA
is found in a patient with HF, optimizing medical therapy using
currently published heart failure care guidelines is of foremost
importance.54 In cases where CSA persists despite aggressive
treatment of heart failure, PAP-based therapies have, until
recently, been the treatment of choice. However, two large,
randomized controlled studies of PAP therapy—CANPAP and
SERVE-HF—have raised concerns about their safety and
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preliminary trials of other therapies, such as nocturnal oxygen
supplementation, atrial pacing, pharmacologic agents (e.g.,
theophylline and acetazolamide), and nocturnal carbon diox-
ide administration, have shown them to offer some beneﬁt in
reducing CSA and/or its symptoms, but none as yet have
undergone large-scale, prospective, randomized trials to
establish their long-term safety and efﬁcacy. Another therapy,
transvenous stimulation of the phrenic nerve, may offer an
important new way of treating CSA in patients with heart
failure. Active research with this system is currently ongoing.
Cardiovascular clinicians are encouraged to closely monitor
the relevant literature to remain abreast of emerging options
for treating this important comorbidity in the heart failure
population.
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